Default sorting
Show
  • CORNEIL 5_dieu_tri_ho_tro_suy_tim

    CORNEIL 5

    [pdf-embedder url="https://davipharm.info/wp-content/uploads/Toa-CORNEIL-TT-01_cv-5393e.2024.pdf"] 
  • CORNEIL-2.5_dieu_tri_ho_tro_suy_tim

    CORNEIL-2,5

    [pdf-embedder url="https://davipharm.info/wp-content/uploads/CORNEIL-25-0049.T2.pdf"] 
  • COURTOIS_dieu_tri_tang_lipit_mau

    COURTOIS

    [pdf-embedder url="https://davipharm.info/wp-content/uploads/COURTOIS_02.pdf"] 
  • Dasarab_giam_nguy_co_tai _bien_tim_mach

    DASARAB

    [pdf-embedder url="https://davipharm.info/wp-content/uploads/DASARAB_06-DOT-162-2.pdf"]
  • DEMBELE_dieu_tri_huyet_ap

    DEMBELE

    [pdf-embedder url="https://davipharm.info/wp-content/uploads/DEMBELE_02.pdf"]
  • DEMBELE-HCTZ_dieu_tri_huyet_ap

    DEMBELE-HCTZ

    [pdf-embedder url="https://davipharm.info/wp-content/uploads/DEMBELE-HCTZ_01.pdf"]

  • ESSEIL-10

    Cilnidipin is indicated for the treatment of hypertension. This is only the preview. Please check here for the full indication.

  • ESSEIL-5

    Cilnidipin is indicated for the treatment of hypertension. This is only the preview. Please check here for the full indication.
  • EZVASTEN_dieu_tri_tang_cholesterol_mau

    EZVASTEN

    [pdf-embedder url="https://davipharm.info/wp-content/uploads/EZVASTEN_04.pdf"]
  • FRANILAX_dieu_tri_phu_khang_thuoc

    FRANILAX

    [pdf-embedder url="https://davipharm.info/wp-content/uploads/FRANILAX_0097.T1.pdf"]
  • GENSLER_dieu_tri_tang_huyet_ap

    GENSLER

    [pdf-embedder url="https://davipharm.info/wp-content/uploads/GENSLER_02.pdf"]

  • GON SA ATZETI

    Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due…